Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amid a complex narrative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback